Our findings in PBL of CRC patients with 10‐year follow‐up data suggest that PBX3 hypermethylation is an independent predictor to better OS of CRC patients, especially in patients with stage III or colon cancer. This evidence concerns the gene PBX3 and malignant colon neoplasm.